Potential role of everolimus in inducing cholestasis.
Pantano
F
F
Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy. Electronic address: f.pantano@unicampus.it.
Santini
D
D
Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
Guida
F
F
Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
Vincenzi
B
B
Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
Tonini
G
G
Department of Medical Oncology, University Campus Bio-Medico, Rome, Italy.
D000970:Antineoplastic Agents / Q000009:adverse effects / Q000494:pharmacology; D002292:Carcinoma, Renal Cell / Q000188:drug therapy* / Q000473:pathology; D002779:Cholestasis / Q000139:chemically induced*; D019008:Drug Resistance, Neoplasm / Q000187:drug effects; D000068338:Everolimus; D006801:Humans; D007680:Kidney Neoplasms / Q000188:drug therapy* / Q000473:pathology; D009362:Neoplasm Metastasis; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D016879:Salvage Therapy; D020123:Sirolimus / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000494:pharmacology
D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D000068338:Everolimus; D020123:Sirolimus